Employers Use Carrots, Sticks, Other Tactics to Boost Biosimilar Use
-
May 08, 2025
As fiduciaries, employers must act in the best interests of their employees and plan, but when it comes to biosimilars, some are not fully promoting them over higher-cost, rebatable reference drugs. During a recent webinar hosted by Midwest Business Group on Health (MBGH), employers including United Airlines and Caterpillar Inc. shared details of their successful efforts to move employees onto the cost-saving drugs.
MBGH also unveiled an Employer Action Brief on biosimilars with the same title as the webinar: Improved Adoption of Biosimilars by Employers Matters.
Even though uptake of the agents could be much better, they produced more than $12.4 billion in savings in 2024, according to the Association for Accessible Medicines. Overall, since the first biosimilar launched in the U.S. in 2015, they have produced more than $36 billion in savings and have had more than 344 million patient days of therapy.
Read more
© 2025 MMIT
The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.